Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Double-blinded Placebo-Controlled Parallel-Group Randomized Clinical Trial of Efficacy, Safety and Choice of an Optimum Dose of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections in Adults

NCT03455491 is registered in ClinicalTrials.gov with PHARMENTERPRISES LLC as lead sponsor.

NCT NCT03455491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03455491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Double-blinded Placebo-Controlled Parallel-Group Randomized Clinical Trial of Efficacy, Safety and Choice of an Optimum Dose of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections in Adults
Lead sponsor
PHARMENTERPRISES LLC
Phase
Phase 2
Overall status
Completed
Start date
February 12, 2018
Completion date
June 28, 2018
Enrollment
120 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory viral infections, influenza